An update on alopecia areata

Kos, Liborka; Conlon, Joseph M.

doi:10.1097/mop.0b013e32832db986

Cited by 37 publications

(40 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A phase II, placebo-controlled trial of efalizumab treatment showed no statistically significant effect on hair regrowth, quality-of-life, or changes in biologic markers of disease severity in patients with alopecia areata. 2 Development of alopecia areata during biological therapy of psoriasis shows features of a "biological drug-induced Renbök phenomenon". The Renbök phenomenon or inverse Köbner phenomenon refers to normal hair growth in psoriatic lesions observed in patients with coexisting psoriasis and alopecia areata.…”

Section: Figure 1 Hair Loss In the Patient Treated With Ustekinumab (mentioning

confidence: 99%

“…1 In both diseases an autoimmune process is the likely pathogenic mechanism, and both show at least partial response to classical immunosuppressive therapy. 2,3 Attempts to treat alopecia areata with biological, immunosuppressive, anti-psoriasis drugs, which target specific molecules, such as tumor necrosis alpha (adalimumab, etanercept, infliximab), CD2 (alefacept) or CD11a (efalizumab) were unsuccessful. 4 This may lead to the in indirect conclusion that these molecules do not play a key role in alopecia areata.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Alopecia areata developing paralell to improvement of psoriasis during ustekinumab therapy

Słowińska¹,

Kardynał²,

Warszawik³

et al. 2010

J Dermatol Case Rep

View full text Add to dashboard Cite

Background: Ustekinumab is a new immunosuppressive anti-psoriasis agent. The drug targets the p40 subunit of IL-12 and IL-23 and indirectly inhibits cytokine production by Th17 cells.Main Observations: We present a case of a 36-year-old male patient with psoriasis, who received ustekinumab therapy, applied in 45mg subcutaneous injections at week 0, 4 and than every 12 weeks. After 7 months of therapy PASI decreased from 10,1 to 0,9. At this phase of therapy he developed two patches of alopecia areata on the scalp. The diagnosis was made based on clinical appearance and was confirmed by trichoscopy (hair and scalp dermoscopy) and reflectance confocal microscopy. The development of alopecia areata was preceded by emotional stress and dental infection.Conclusion: Ustekinumab seems an unlikely cause of alopecia areata in this patient. However, lack of efficacy is preventing hair loss may indicate that interleukin-12 cytokine family is not a key player in pathogenesis of alopecia areata.

show abstract

Section: Figure 1 Hair Loss In the Patient Treated With Ustekinumab (mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Alopecia areata developing paralell to improvement of psoriasis during ustekinumab therapy

Słowińska¹,

Kardynał²,

Warszawik³

et al. 2010

J Dermatol Case Rep

View full text Add to dashboard Cite

show abstract

“…[12][13][14][15][16] İnfantil dönemde görülen alopesi nedenlerinin ayırıcı tanısına giren hastalıklar Tablo 1'de görülmektedir. [1][2][3][5][6][7][8][9][10][12][13][14][15][16] Bu olguda SHA hayatın 6. ayından sonra tedricen gelişmiş idi, ancak SHA'lı birçok hastada alopesinin doğumda ya da doğumdan hemen sonra başladığı bildirilmiştir. Bu olguda hayatın genellikle ilk 3 ayında görülen SHA'nın ilk aylarda aile tarafından fark edilememiş olması da dikkat çeki-cidir.…”

Section: Discussionunclassified

Persistent Halo Scalp Ring Alopecia in a-9-Months Old Infant: Case Report

Üstüner¹,

Balevi²,

Özdemir³

et al. 2017

Turkiye Klinikleri J Dermatol

View full text Add to dashboard Cite

“…Alopesi areata (AA) insidansı yılda 20,2/100,000 olan, saç, sakal gibi vücudun kıllı bölgelerini etkileyen otoimmün bir hastalıktır [1][2][3] . Alopesi areatanın patogenezi tam olarak bilinmemekte ise de günümüzdeki baskın görüş, genetik yatkınlığı olan bireylerde, çevresel tetikleyicilerle kıl foliküllerine karşı gelişen organ spesifik otoimmün bir hastalık olduğu yönündedir 1,2 .…”

Section: Introductionunclassified

“…Alopesi areatanın patogenezi tam olarak bilinmemekte ise de günümüzdeki baskın görüş, genetik yatkınlığı olan bireylerde, çevresel tetikleyicilerle kıl foliküllerine karşı gelişen organ spesifik otoimmün bir hastalık olduğu yönündedir 1,2 . Bu çalışmada polikliniğimize başvuran AA'lı hastaların, klinik ve demografik özellikleri ile hastalık seyrindeki kötü prognostik faktörleri incelenerek, AA'nın Türkiye'deki epidemiyolojik özelliklerinin tanınmasına katkı amaçlandı 1,4,5 .…”

Section: Introductionunclassified

An investigation of poor prognostic factors in patients with alopecia areata and their relatives

Duman¹,

Köse²,

İşsever³

2015

TURKDERM

View full text Add to dashboard Cite

Background and Design: Alopecia areata (AA) is characterized by non-ciatricial hair loss with exacerbations and remissions. Although its etiopathogenesis is not known, autoimmune factors have been suggested. Our aim was to make contribution to the epidemiological properties of AA in Turkey, and to determine the poor prognostic factors that affect the course of the disease. Materials and Methods: One hundred and thirty-four patients who applied to the dermatology and venereology outpatient clinic of Istanbul Medical Faculty were included in the study. The patients were retrospectively investigated in terms of age, gender, clinical type, the area affected by alopecia, severity of the disease, number of relapses, disease duration, age at disease onset, presence of nevus flammeus, nail involvement, history of emotional and/or physical stress, family history of AA, family and personal history of atopy. Results: Of the 134 patients, 79 (59 percent) were male, 55 (41 percent) were female and M/F ratio was 1.4/1. The clinical type was AA in 86.5%, alopecia totalis (AT) in 3.7% and alopecia universalis (AU) in 9.7% of the cases. The most common involvement was the scalp in both genders and 92.1% of them had patch pattern. Severe involvement was found to be significant in the female patients (p=0.029), in those with juvenile onset (p=0.001), and ≥1 year of disease duration (p=0.001) as well as in the presence of nevus flammeus (p=0.017) and nail involvement (p=0.015). A family history of AA was present in 27.6% of the cases and it was more common in the juvenile group (p=0.034). There was no association between the severity of the disease and atopy.

show abstract

An update on alopecia areata

Abstract: Although multiple potential susceptibility loci have been implicated, the genetics of alopecia areata is still unclear. The role of any potential environmental contributors is also unclear. Quality evidence for efficacy of currently used treatments for alopecia areata is lacking.

Cited by 37 publications

References 49 publications

Alopecia areata developing paralell to improvement of psoriasis during ustekinumab therapy

Alopecia areata developing paralell to improvement of psoriasis during ustekinumab therapy

Persistent Halo Scalp Ring Alopecia in a-9-Months Old Infant: Case Report

An investigation of poor prognostic factors in patients with alopecia areata and their relatives

Contact Info

Product

Resources

About